Retatrutide
The sentences below are limited to one FDA page opened for this draft.
What the opened sources say
Section titled “What the opened sources say”- FDA says retatrutide cannot be used in compounding under federal law, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition.
- FDA says it has warned telehealth companies marketing unapproved retatrutide, distributors selling it to compounders, and outsourcing facilities repackaging it.
- FDA also names retatrutide among unapproved drugs sold with false research-use or not-for-human-consumption labels, including products sold for human use with dosing instructions.
Not stated here
Section titled “Not stated here”This page does not describe receptor pharmacology or trial results. Those were not copied from a paper or label.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Sources
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (primary, accessed 2026-11-20)
Referenced by
A link from another wiki page is not evidence. Facts should point at the sources above.